UPDATED Mar 01, 2024
The market has not yet priced in the high-growth prospects for these companies, featuring low PEG ratio (less than 0.5), high future growth outlook and good value on the Snowflake.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
4979LuxNet | NT$156.00 | -5.5% | 223.3% | NT$20.6b | NT$210.00 | PE54.6x | E117.5% | 0.04% | Tech | ||
6620Handa Pharmaceuticals | NT$176.50 | 1.4% | -4.6% | NT$24.9b | NT$200.00 | PE35.2x | E78.9% | n/a | Pharmaceuticals & Biotech |